HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement Labeling Toll-Free AER Number Provision Included In House Bill

This article was originally published in The Tan Sheet

Executive Summary

Ephedrine alkaloid-containing dietary supplements would be prohibited from sale to people under 18 and limited to "behind-the-counter" distribution under a bill introduced by freshman Rep. Susan Davis (D-Calif.) Oct. 9.

You may also be interested in...

Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter

The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery

Sport Supplement High School Education Program Urged In California Bill

All secondary schools in California would be required to instruct students on the effects of performance-enhancing substances under a state bill recently introduced by Sen. Jackie Speier (D)

CAM Commission AER Proposal Unfairly Targets Supplements - CRN

Dietary supplement manufacturers should not be required to report serious adverse events to FDA, the Council for Responsible Nutrition asserts in Oct. 19 comments on WHCCAMP draft recommendations.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts